Author(s): Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.
Question: Should Ivermectin compared to Placebo be used for COVID-19 patients?
Setting: Inpatient/Outpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Ivermectin	Placebo	Relative (95% CI)	Absolute (95% CI)	
All-cause mortality											
1	randomised trials	serious [a]	not serious	not serious	serious [b]	none	0/275 (0.0%)	1/198 (0.5%)	**RR 0.24** (0.01 to 5.87)	**4 fewer per 1.000** (from 5 fewer to 25 more)	⊕⊕◯◯ LOW
Progression of COVID-19 disease											
1	randomised trials	serious [a]	not serious	not serious	not serious	none	5/275 (1.8%)	7/198 (3.5%)	**RR 0.51** (0.17 to 1.60)	**17 fewer per 1.000** (from 29 fewer to 21 more)	⊕⊕⊕◯ MODERATE
Number of patients with respiratory distress syndrome											
1	randomised trials	serious [a]	not serious	not serious	not serious	none	No event reported				⊕⊕⊕◯ MODERATE
Number of patients with any adverse event											
1	randomised trials	serious [a]	not serious	not serious	not serious	none	211/275 (76.7%)	161/198 (81.3%)	**RR 0.94** (0.86 to 1.04)	**49 fewer per 1.000** (from 114 fewer to 33 more)	⊕⊕⊕◯ MODERATE
Number of patients with serious adverse events											
1	randomised trials	serious [a]	not serious	not serious	not serious	none	20/275 (7.3%)	5/198 (2.5%)	**RR 2.88** (1.10 to 7.54)	**47 more per 1.000** (from 3 more to 165 more)	⊕⊕⊕◯ MODERATE

Explanations
a. Downgraded of one level for high risk of attrition bias and unclear risk of detection bias
b. Downgraded of one level for wide Confidence Interval

References

1. López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martines E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA. Published online March 04, 2021. doi:10.1001/jama.2021.3071